Nucleic Acid Testing Market Size, Share and Global Trend By Technology (Polymerase Chain Reaction, Ligase Chain Reaction, Transcription-mediated Amplification, Whole Genome Sequencing), By Application (Disease Diagnosis, Forensic Testing, Personalized Medicine, Others), By End User (Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes), and Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
A nucleic acid test (NAT), also known as nucleic acid amplification test (NAAT), is an innovative technique used for the detection of a specific nucleic acid, virus or bacteria that acts as a disease-causing pathogen from biological samples such as blood, tissues, urine, etc. The major three steps involved in the nucleic acid test are sample collection and nucleic acid (NA) extraction, target NA amplification, and target amplicon NA detection. The nucleic acid test includes an amplification step for the amplification of the genetic material. There are several techniques for amplification, including strand displacement assay (SDA), polymerase chain reaction (PCR), or transcription-mediated assay (TMA). New and innovative NAT testing platforms are being introduced in the market, which is further expected to augment the demand for nucleic acid testing in the global market from 2019-2026. For instance, a team of researchers from National University of Singapore (NUS) developed a portable, easy-to-use device for quick and accurate screening of diseases named as envision (enzyme-assisted nanocomplexes for visual identification of nucleic acids) in September 2018. This device is designed for the detection of a wide range of diseases, including emerging infectious diseases such as Zika, Ebola and others.
The increased demand for the nucleic acid test kits from blood transfusion centers and the blood banks are anticipated to positively impact the global nucleic acid testing market. Increase in demand for PCR kits and technological advancement in both research & health care industries are the major drivers of the global nucleic acid testing market. Also, increased prevalence of genetic diseases, cancer, and infectious diseases such as hepatitis, dengue, malaria, and others are expected to fuel the global nucleic acid testing market.
To gain extensive insights into the market, Request for Customization
The need for dedicated infrastructure facility, lack of trained technical expertise, and high sensitivity are the factors that can hamper the growth in the global nucleic acid testing market.
KEY PLAYERS COVERED
Some of the major companies that are present in the global nucleic acid testing market are Abbott, BD, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Siemens AG, Hologic Inc., bioMérieux SA, Novartis AG, F. Hoffmann-La Roche Ltd., Sequenom, Tecan Trading AG., and others.
SEGMENTATION
SEGMENTATION | DETAILS |
By Technology | · Polymerase Chain Reaction (PCR) · Ligase Chain Reaction (LCR) · Transcription-mediated Amplification (TMA) · Whole Genome Sequencing · Others |
By Application | · Disease Diagnosis · Forensic Testing · Personalized Medicine · Others |
By End User | · Hospitals · Specialty Clinics · Diagnostic Centers · Academic & Research Institutes · Others |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
Based on application, the personalized medicine segment is projected to register a remarkable growth owing to the increased focus on personalized medicine and a gradual shift towards personalized medicines for the treatment of diseases, especially cancer and infectious diseases.
KEY INSIGHTS
Epidemiology of infectious disease for key countries
The regulatory scenario for key countries
New product launch
Recent industry developments such as partnerships, mergers, and acquisitions
REGIONAL ANALYSIS
North America followed by Europe, are the two largest markets for Nucleic Acid Testing (NAT) at present, and they are expected to account for a large proportion of the market in the forecast period as well. The increased investments in the diagnostics and research sectors combined with the increasing prevalence of infectious diseases are expected to favor the nucleic acid testing market in North America during the forecast period. Asia Pacific is expected to register a comparatively higher CAGR, owing to factors such as increasing awareness of the nucleic acid testing along with a shift of research institutes and contract research organizations from developed western countries to emerging countries in Asia Pacific.
Key Industry Developments |
· In January 2019, Abingdon Health launched new version of successful NALFIA rapid test used for the detection of DIG/Biotin and /or FITC (Or FAM)/biotin -labelled analytes. · In September 2018, the scientists from the National University of Singapore developed a portable platform for the point-of-care nucleic acid test which can be used for the diagnosis of various diseases. The device is named as “enVision” (enzyme-assisted nanocomplexes for visual identification of nucleic acids). · In October 2017, F. Hoffmann-La Roche Ltd. received FDA approval for the cobas Zika, a nucleic acid screening test for use on the cobas 6800/8800 systems · In September 2017, Advanced Analytical Technologies, Inc. (AATI) partnered with Illumina, Inc. for supporting the co-marketing activities involving the company’s Fragment Analyzer Automated CE Systems used for the quality control (QC) analysis of nucleic acids in Illumina next-generation sequencing (NGS) |
- Ongoing
- 2023
- 2019-2022
-
Get in Touch with Us
-
US +1 833 909 2966 ( Toll Free )
-
